# HERA, NSABP B-31 & NCCTG N9831 (adjuvant trastuzumab)

Source: https://onco.cc/trials/hera-b31-n9831/  
OnCo record `hera-b31-n9831` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Three trials reported together in 2005 showed that a year of trastuzumab after surgery cuts the risk of dying from HER2-positive breast cancer by about a third.

## Summary

HERA, NSABP B-31 and NCCTG N9831, led by trial NCT00045032 and sponsored by BIG, NSABP and NCCTG, were three adjuvant trials reported together in 2005 that showed a year of trastuzumab after surgery cuts the risk of dying from HER2-positive breast cancer by about a third. Across roughly 9,000 women the joint B-31 and N9831 analysis and the HERA trial both showed large, durable improvements in disease-free and overall survival at ten and eleven years despite heavy crossover in HERA, turning the worst breast cancer subtype into one of the most curable, and HERA also showed that two years of trastuzumab is no better than one. OnCo links them to HER2 as a target, trastuzumab, Barbara Bradfield, Norman Wolmark, Charles E. Geyer Jr., David Cameron, Martine Piccart and the NSABP Foundation. Whether shorter courses can match a year, as PERSEPHONE later asked, is the question that followed.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-07
- Registry id: NCT00045032
- Phase: 3
- Setting: Adjuvant HER2+ early breast cancer: one year of trastuzumab with or after chemotherapy vs chemotherapy alone
- Sponsor: BIG / NSABP / NCCTG
- Enrolled: 9000
- Result: B-31/N9831 10-year OS 84% vs 75.2%, HR 0.63.
- Outcomes: 10-year overall survival (B-31/N9831): Chemotherapy + trastuzumab 84% vs Chemotherapy alone 75.2%, HR 0.63; Disease-free survival (B-31/N9831): Chemotherapy + trastuzumab vs Chemotherapy alone, HR 0.6
- Replication: Four independent adjuvant trials (HERA, B-31, N9831, BCIRG 006) all positive.

## Sources

- ClinicalTrials.gov NCT00045032: https://clinicaltrials.gov/study/NCT00045032

## Connected records

- cancers: [Early HER2-positive breast cancer](https://onco.cc/cancers/her2-positive-early-breast-cancer/), [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [HER2](https://onco.cc/targets/her2/)
- drugs: [Trastuzumab](https://onco.cc/drugs/trastuzumab/)
- companies: [NSABP Foundation](https://onco.cc/companies/nsabp-foundation/)
- people: [Barbara Bradfield](https://onco.cc/people/barbara-bradfield/), [Charles E. Geyer Jr.](https://onco.cc/people/charles-geyer/), [David Cameron](https://onco.cc/people/david-cameron/), [Martine Piccart](https://onco.cc/people/martine-piccart/), [Norman Wolmark](https://onco.cc/people/norman-wolmark/)
- key papers: [11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial](https://onco.cc/key-papers/paper-hera-b31-n9831-lancet-2017-update/), [Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer](https://onco.cc/key-papers/paper-hera-b31-n9831-n-engl-j-med-2005/)
- roadmaps: [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/hera-b31-n9831.json